Pioglitazone: Mechanism of action

International Journal of Clinical Practice, Supplement

Volumn , Issue 121, 2001, Pages 13-18

  Smith, U ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 3 [4 (2 METHYL 2 PHENYLPROPOXY)PHENYL]PROPIONIC ACID ETHYL ESTER; AL 321; CIGLITAZONE; FATTY ACID; GLUCOSE TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ADIPOSE TISSUE; CARBOHYDRATE METABOLISM; CONFERENCE PAPER; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

BLOOD GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; NUCLEAR PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0034804726     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. The PPARs: From orphan receptors to drug discovery
2. PPARγ, the ultimate thrifty gene
3. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
4. 12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: Possible involvement in impairment of insulin secretion in individuals with type 2 diabetes
5. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
6. Antidiabetic drugs present and future: Will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
7. Decreased expression of glucose transporter in muscle from insulin-resistant patients
8. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin dependent diabetes mellitus and obesity
9. Regulation of glucose transport by pioglitazone in cultured muscle cells
10. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability
11. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone
12. Effect of pioglitazone on glucose tolerance and insulin sensitivity in diet-controlled type 2 diabetic subjects
13. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
14. Mechanism of free fatty-acid-induced insulin resistance in humans
15. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM
16. Effect of pioglitazone on glucose metabolism in sulfonylurea-treated patients with type 2 diabetes
17. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle
18. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
19. Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes
20. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin
21. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT 2 and phosphoenolpyruvate carboxykinase expression
22. Insulin sensitisation in diabetic rat liver by an antihyperglycemic agent
23. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats
24. Acute effects of pioglitazone on glucose metabolism in perfused rat liver
25. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output
26. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance
27. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats
28. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells
29. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat
30. Antidiabetic agent pioglitazone increases insulin receptors on 3T3-L1 adipocytes
31. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats
32. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function
33. 2+ mobilization and cell proliferation in vascular smooth muscle cells
34. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
35. Pioglitazone: The future